Introducing GPEx® Lightning: Leveraging Proven Technology to Speed Your Path to First-In-Human Studies

Join Catalent Biologics for this On-Demand Webinar:

Leveraging Proven Technology to Speed Your Path to First-In-Human Studies

AVAILABLE ON-DEMAND

Note: If you have already registered for this webinar, please click t his link and use your email to login to the platform again

Event Details:

With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 16 biopharmaceutical drugs using GPEx® cell line development technology and manufactured 45+ commercially approved products. Catalent recently introduced GPEx Lightning, a fast, flexible way to shorten the path to production of phase 1 material. During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.

LEARN MORE ABOUT:

Novel, non-viral gene insertion technology for CHO cell line engineering
Characteristics of cell line engineering technologies that help develop a wide variety of therapeutic proteins
How high pool stability and expression can lead to shorter development timelines.

Featured Speaker:

First Name*

Last Name*

Email*

Job Level*

Company*

Country*

Phone

Primary Area of Interest*

Reason for Interest*

Keep Me Informed (Opt In)

Gregory Bleck

Vice President, R&D, Biologics

Catalent

By submitting this form you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy | Privacy Shield Statement.